• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs.锌依赖性组蛋白去乙酰化酶的去酰基酶和去乙酰酶活性比较
ACS Chem Biol. 2017 Jun 16;12(6):1644-1655. doi: 10.1021/acschembio.7b00321. Epub 2017 May 4.
2
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.催化和抑制 IIb 类组蛋白去乙酰化酶中的化学多功能性。
Acc Chem Res. 2024 Apr 16;57(8):1135-1148. doi: 10.1021/acs.accounts.3c00801. Epub 2024 Mar 26.
3
Chemical and structural biology of protein lysine deacetylases.蛋白质赖氨酸脱乙酰酶的化学与结构生物学
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(5):297-321. doi: 10.2183/pjab.93.019.
4
HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity.HDAC 3选择性抑制剂RGFP966通过减弱NF-κB p65转录活性,在RAW 264.7巨噬细胞和小鼠精密切割肺切片中表现出抗炎特性。
Biochem Pharmacol. 2016 May 15;108:58-74. doi: 10.1016/j.bcp.2016.03.010. Epub 2016 Mar 16.
5
Erasers of histone acetylation: the histone deacetylase enzymes.组蛋白乙酰化的橡皮擦:组蛋白去乙酰化酶。
Cold Spring Harb Perspect Biol. 2014 Apr 1;6(4):a018713. doi: 10.1101/cshperspect.a018713.
6
Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.使用组蛋白去乙酰化酶抑制剂分析组蛋白去乙酰化酶与翻译的相关性。
Methods Mol Biol. 2017;1510:77-91. doi: 10.1007/978-1-4939-6527-4_6.
7
Non-sirtuin histone deacetylases in the control of cardiac aging.非沉默调节蛋白组蛋白去乙酰化酶在心脏衰老控制中的作用
J Mol Cell Cardiol. 2015 Jun;83:14-20. doi: 10.1016/j.yjmcc.2015.03.010. Epub 2015 Mar 16.
8
HDACs and HDAC Inhibitors in Cancer Development and Therapy.组蛋白去乙酰化酶及组蛋白去乙酰化酶抑制剂在癌症发生与治疗中的作用
Cold Spring Harb Perspect Med. 2016 Oct 3;6(10):a026831. doi: 10.1101/cshperspect.a026831.
9
The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart.乙酰化和磷酸化的串扰:HDAC 抑制剂在心脏中的新兴新作用。
Int J Mol Sci. 2018 Dec 28;20(1):102. doi: 10.3390/ijms20010102.
10
Members of the histone deacetylase superfamily differ in substrate specificity towards small synthetic substrates.组蛋白脱乙酰酶超家族的成员对小型合成底物的底物特异性有所不同。
Biochem Biophys Res Commun. 2004 Nov 19;324(3):1116-23. doi: 10.1016/j.bbrc.2004.09.155.

引用本文的文献

1
In-Cell Testing of Zinc-Dependent Histone Deacetylase Inhibitors in the Presence of Class-Selective Fluorogenic Substrates: Potential and Limitations of the Method.在存在类别选择性荧光底物的情况下对锌依赖性组蛋白去乙酰化酶抑制剂进行细胞内测试:该方法的潜力与局限性
Biomedicines. 2024 May 29;12(6):1203. doi: 10.3390/biomedicines12061203.
2
Hdac3-deficiency increases senescence-associated distention of satellite DNA and telomere-associated foci in osteoprogenitor cells.组蛋白去乙酰化酶3缺失会增加骨祖细胞中卫星DNA的衰老相关扩张和端粒相关灶。
J Bone Miner Res. 2024 Aug 5;39(7):994-1007. doi: 10.1093/jbmr/zjae085.
3
Epigenetic meets metabolism: novel vulnerabilities to fight cancer.表观遗传学与代谢:攻克癌症的新靶点。
Cell Commun Signal. 2023 Sep 21;21(1):249. doi: 10.1186/s12964-023-01253-7.
4
Significance of Five-Membered Heterocycles in Human Histone Deacetylase Inhibitors.五元杂环在人类组蛋白去乙酰化酶抑制剂中的意义。
Molecules. 2023 Jul 27;28(15):5686. doi: 10.3390/molecules28155686.
5
TgKDAC4: A Unique Deacetylase of ' Apicoplast.TgKDAC4:顶质体的一种独特的脱乙酰酶。
Microorganisms. 2023 Jun 12;11(6):1558. doi: 10.3390/microorganisms11061558.
6
LP342, a novel histone deacetylase inhibitor, decreases nitro-oxidative stress, mitochondrial dysfunction and hepatic ischaemia/reperfusion injury in mice.新型组蛋白去乙酰化酶抑制剂LP342可减轻小鼠的硝基氧化应激、线粒体功能障碍及肝脏缺血/再灌注损伤。
RPS Pharm Pharmacol Rep. 2023 Apr 4;2(2):rqad013. doi: 10.1093/rpsppr/rqad013. eCollection 2023 Apr.
7
Dynamic acylome reveals metabolite driven modifications in .动态酰基化组揭示了代谢物驱动的修饰……(原文此处不完整)
Front Microbiol. 2022 Nov 7;13:1018220. doi: 10.3389/fmicb.2022.1018220. eCollection 2022.
8
Modulation of cellular processes by histone and non-histone protein acetylation.组蛋白和非组蛋白蛋白乙酰化对细胞过程的调节。
Nat Rev Mol Cell Biol. 2022 May;23(5):329-349. doi: 10.1038/s41580-021-00441-y. Epub 2022 Jan 18.
9
Targeting HDAC Complexes in Asthma and COPD.针对哮喘和慢性阻塞性肺疾病中的组蛋白去乙酰化酶复合物
Epigenomes. 2019 Sep 7;3(3):19. doi: 10.3390/epigenomes3030019.
10
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases.非羟肟酸锌结合基团作为组蛋白去乙酰化酶的弹头。
Molecules. 2021 Aug 25;26(17):5151. doi: 10.3390/molecules26175151.

本文引用的文献

1
HDAC6 deacetylates p53 at lysines 381/382 and differentially coordinates p53-induced apoptosis.组蛋白去乙酰化酶6(HDAC6)使p53的赖氨酸381/382位点去乙酰化,并以不同方式协调p53诱导的细胞凋亡。
Cancer Lett. 2017 Apr 10;391:162-171. doi: 10.1016/j.canlet.2017.01.033. Epub 2017 Jan 30.
2
Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.用于急性髓系白血病的含变构酰肼的I类组蛋白去乙酰化酶抑制剂的研发
J Med Chem. 2016 Nov 10;59(21):9942-9959. doi: 10.1021/acs.jmedchem.6b01385. Epub 2016 Oct 26.
3
An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.一组等化学成因的抑制剂,用于确定组蛋白去乙酰化酶在β细胞保护中的治疗潜力。
ACS Chem Biol. 2016 Feb 19;11(2):363-74. doi: 10.1021/acschembio.5b00640. Epub 2015 Dec 7.
4
Inhibition of Histone Deacetylases Permits Lipopolysaccharide-Mediated Secretion of Bioactive IL-1β via a Caspase-1-Independent Mechanism.组蛋白去乙酰化酶的抑制通过一种不依赖半胱天冬酶-1的机制使脂多糖介导的生物活性白细胞介素-1β分泌成为可能。
J Immunol. 2015 Dec 1;195(11):5421-31. doi: 10.4049/jimmunol.1501195. Epub 2015 Oct 30.
5
Identification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.具有苯甲酰肼支架的组蛋白脱乙酰酶抑制剂的鉴定,该抑制剂可选择性抑制I类组蛋白脱乙酰酶。
Chem Biol. 2015 Feb 19;22(2):273-84. doi: 10.1016/j.chembiol.2014.12.015.
6
Lysine glutarylation is a protein posttranslational modification regulated by SIRT5.赖氨酸戊二酰化是一种由SIRT5调节的蛋白质翻译后修饰。
Cell Metab. 2014 Apr 1;19(4):605-17. doi: 10.1016/j.cmet.2014.03.014.
7
Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease.设计、合成和强效、选择性的 IIa 类组蛋白去乙酰化酶(HDAC)抑制剂的生物学评价,作为治疗亨廷顿病的潜在疗法。
J Med Chem. 2013 Dec 27;56(24):9934-54. doi: 10.1021/jm4011884. Epub 2013 Dec 5.
8
Identification of highly selective and potent histone deacetylase 3 inhibitors using click chemistry-based combinatorial fragment assembly.基于点击化学的组合片段组装法鉴定高选择性和强效的组蛋白去乙酰化酶 3 抑制剂。
PLoS One. 2013 Jul 16;8(7):e68669. doi: 10.1371/journal.pone.0068669. Print 2013.
9
SIRT6 regulates TNF-α secretion through hydrolysis of long-chain fatty acyl lysine.SIRT6 通过水解长链脂肪酸酰基辅酶 A 的赖氨酸来调节 TNF-α 的分泌。
Nature. 2013 Apr 4;496(7443):110-3. doi: 10.1038/nature12038.
10
Regulation of HMGB1 release by inflammasomes.炎性小体调控 HMGB1 的释放。
Protein Cell. 2013 Mar;4(3):163-7. doi: 10.1007/s13238-012-2118-2. Epub 2013 Mar 13.

锌依赖性组蛋白去乙酰化酶的去酰基酶和去乙酰酶活性比较

Comparison of the Deacylase and Deacetylase Activity of Zinc-Dependent HDACs.

作者信息

McClure Jesse J, Inks Elizabeth S, Zhang Cheng, Peterson Yuri K, Li Jiaying, Chundru Kalyan, Lee Bradley, Buchanan Ashley, Miao Shiqin, Chou C James

机构信息

Medical University of South Carolina , College of Pharmacy, Charleston, South Carolina, United States.

China Agricultural University , Department of Applied Chemistry, Beijing, China.

出版信息

ACS Chem Biol. 2017 Jun 16;12(6):1644-1655. doi: 10.1021/acschembio.7b00321. Epub 2017 May 4.

DOI:10.1021/acschembio.7b00321
PMID:28459537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5567816/
Abstract

The acetylation status of lysine residues on histone proteins has long been attributed to a balance struck between the catalytic activity of histone acetyl transferases and histone deacetylases (HDAC). HDACs were identified as the sole removers of acetyl post-translational modifications (PTM) of histone lysine residues. Studies into the biological role of HDACs have also elucidated their role as removers of acetyl PTMs from lysine residues of nonhistone proteins. These findings, coupled with high-resolution mass spectrometry studies that revealed the presence of acyl-group PTMs on lysine residues of nonhistone proteins, brought forth the possibility of HDACs acting as removers of both acyl- and acetyl-based PTMs. We posited that HDACs fulfill this dual role and sought to investigate their specificity. Utilizing a fluorescence-based assay and biologically relevant acyl-substrates, the selectivities of zinc-dependent HDACs toward these acyl-based PTMs were identified. These findings were further validated using cellular models and molecular biology techniques. As a proof of principal, an HDAC3 selective inhibitor was designed using HDAC3's substrate preference. This resulting inhibitor demonstrates nanomolar activity and >30 fold selectivity toward HDAC3 compared to the other class I HDACs. This inhibitor is capable of increasing p65 acetylation, attenuating NF-κB activation, and thereby preventing downstream nitric oxide signaling. Additionally, this selective HDAC3 inhibition allows for control of HMGB-1 secretion from activated macrophages without altering the acetylation status of histones or tubulin.

摘要

长期以来,组蛋白上赖氨酸残基的乙酰化状态一直被认为是组蛋白乙酰转移酶和组蛋白去乙酰化酶(HDAC)催化活性之间达到的一种平衡。HDAC被确定为组蛋白赖氨酸残基乙酰化翻译后修饰(PTM)的唯一去除者。对HDAC生物学作用的研究也阐明了它们作为非组蛋白赖氨酸残基乙酰化PTM去除者的作用。这些发现,再加上高分辨率质谱研究揭示了非组蛋白赖氨酸残基上存在酰基PTM,提出了HDAC作为酰基和乙酰基PTM去除者的可能性。我们推测HDAC发挥这种双重作用,并试图研究它们的特异性。利用基于荧光的检测方法和生物学相关的酰基底物,确定了锌依赖性HDAC对这些基于酰基的PTM的选择性。这些发现通过细胞模型和分子生物学技术得到了进一步验证。作为原理验证,利用HDAC3的底物偏好设计了一种HDAC3选择性抑制剂。与其他I类HDAC相比,这种产生的抑制剂表现出纳摩尔活性和对HDAC3大于30倍的选择性。这种抑制剂能够增加p65乙酰化,减弱NF-κB激活,从而阻止下游一氧化氮信号传导。此外,这种选择性HDAC3抑制能够控制活化巨噬细胞中HMGB-1的分泌,而不改变组蛋白或微管蛋白的乙酰化状态。